<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS: Overall, 119 patients bearing a KRAS mutation in codon 12 were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received cetuximab-based first-line chemotherapy within the Central European Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (CECOG), AIO KRK-0104 or AIO KRK-0306 trials </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Patients with KRAS codon 12 mutant mCRC showed a broad range of outcome when treated with cetuximab-based first-line regimens </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> bearing a KRAS p.G12D mutation showed a strong trend to a more favorable outcome compared to other mutations (overall survival 23.3 vs. 14-18 months; hazard ratio 0.66, range 0.43-1.03) </plain></SENT>
<SENT sid="5" pm="."><plain>An interaction model illustrated that KRAS p.G12C was associated with unfavorable outcome when treated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> plus cetuximab </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The present analysis suggests that KRAS codon 12 mutation may not represent a homogeneous entity in mCRC when treated with cetuximab-based first-line therapy </plain></SENT>
</text></document>